CATALYSTYahoo Finance • 1d ago
Viridian Therapeutics (VRDN) Stock May Look Stretched Against Its Sales BaseYahoo Finance report covering Viridian Therapeutics Inc. (VRDN) market action, institutional positioning, and fundamental catalysts.
Why VRDN Stock surged +2.55% Today — RQD Quant Desk Flash
$25.30 +2.55% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $25.37
Viridian Therapeutics Inc. (VRDN) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $2.79B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on VRDN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is VRDN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Viridian Therapeutics Inc. (NASDAQ: VRDN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $25.30 (+2.55% 1D, market cap $2.79B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, VRDN ranks #359 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does VRDN compare to VCRE and MBX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VRDN carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VCRE (Vicore Pharma Holding AB) holds a D grade (49/100 RQD, P/E N/A, ROIC —, cap $2.76B) and MBX (MBX Biosciences Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -26.4%, cap $2.69B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for VRDN?
▼
Per VRDN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001590750), Viridian Therapeutics Inc. generated $1.02B in revenue (+21.5% YoY), -$342.6M in net income, and -$276.9M in free cash flow against $899.4M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $25.37 (+0.27%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-5.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VRDN)Realized 20D OHLCV Swing Band: ±9.5%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY VRDN SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (33% of score)
20D Institutional Volume Accumulation (±9.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (22% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$18.22+23.1% Next Q
37
Q2 (-2Q)Grade D$22.43+7.4% Next Q
40
Q3 (-1Q)Grade D$24.09+5% Next Q
42
CurrentGrade D$25.30-6.3% Hist 90D α
45
Trajectory: E (37) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a VRDN Turnaround Squeeze
While VRDN currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Big institutional funds and options desks are actively positioning on the bullish side.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($21.68) and Max Pain ($26.57) forces dealer call-delta covering toward $36.00.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $VRDN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VRDN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why VRDN Stock surged +2.55% Today — RQD Quant Desk Flash
Viridian Therapeutics Inc. (VRDN) surged +2.55% to $25.30, trading at 57% of its 52-week range ($13.18 – $34.29). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 57% of its 52-week range ($13.18 – $34.29) with RSI-14 at 69.1 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±9.5% around $25.30 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live VRDN Headlines & Catalysts
MARKET WIREMoomoo • 1d ago
RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $38Moomoo report covering Viridian Therapeutics Inc. (VRDN) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Viridian Therapeutics (NasdaqCM:VRDN) Stock Forecast & Analyst PredictionsSimply Wall St report covering Viridian Therapeutics Inc. (VRDN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
How FDA Approval Will Impact Viridian Therapeutics StockYahoo Finance report covering Viridian Therapeutics Inc. (VRDN) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
VRDN Q3'26 Earnings: revenue estimate is 4.72M USDTradingView report covering Viridian Therapeutics Inc. (VRDN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBusiness Wire • 1d ago
Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026Business Wire report covering Viridian Therapeutics Inc. (VRDN) market action, institutional positioning, and fundamental catalysts.
RISK WATCHSimply Wall St • 1d ago
Analyst Forecasts Just Became More Bearish On Viridian Therapeutics, Inc. (NASDAQ:VRDN)Simply Wall St report covering Viridian Therapeutics Inc. (VRDN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREad-hoc-news.de • 1d ago
Wells Fargo keeps Buy rating for Viridian Therapeutics stock at USD 31 targetad-hoc-news.de report covering Viridian Therapeutics Inc. (VRDN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 1d ago
A $2 Billion Fund Bought These 3 Stocks Last QuarterKey TakeawaysA $2 billion fund’s latest 13F shows its three biggest adds in the quarter ended June 30 were Viridian Therapeutics, Travere Therapeutics, and Legend Biotech. Analysts’ average price targets sit 47% to 111%
MARKET WIREBenzinga • 18d ago
Roche Secures FDA Approval for First At-Home Thyroid Eye Disease TherapyRoche earns FDA approval for Enspryng in thyroid eye disease, offering the only at-home subcutaneous treatment for TED.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VRDN)
- ✓Walkthrough of VRDN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
VRDN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +79.94%⚡ TESTING RESISTANCE
2026-11-03O $24.80H $25.30L $24.67C $25.30VOL 1.71M
RES: $25.35SUP: $18.04SMA50: $21.68SMA200: $21.67
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
VRDN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +21.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on VRDN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for VRDN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VRDN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VRDN)
Health Care Rank #359 of 1015
⚔️ VCRE vs VRDN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (VRDN vs. VCRE, MBX, NRIX, BHC)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Viridian Therapeutics Inc. (VRDN) ranks #359 by composite RQD confidence (45/100, grade D) and #211 by equity capitalization ($2.79B). Within this direct 5-issuer industry benchmark cohort, BHC leads on earnings valuation at 21.2x trailing P/E, while BHC leads on capital efficiency and profitability with 7.6% ROIC and — gross margin. BHC currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with VRDN at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| VRDN
ACTIVE
Viridian Therapeutics Inc. | D | 45/100 | — | — | -35.0% | +2.55% | $2.79B | Benchmark Subject |
| VCRE Vicore Pharma Holding AB | D | 49/100 | — | — | — | -2.14% | $2.76B | /vcre-vs-vrdn → |
| MBX MBX Biosciences Inc. | D- | 40/100 | — | — | -26.4% | -2.63% | $2.69B | /mbx-vs-vrdn → |
| NRIX Nurix Therapeutics Inc. | D | 46/100 | — | — | -35.0% | -4.10% | $2.93B | /nrix-vs-vrdn → |
| BHC Bausch Health Companies Inc. | C+ | 68/100 | 21.2x | — | 7.6% | -2.19% | $3.07B | /bhc-vs-vrdn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001590750 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Viridian Therapeutics Inc. (VRDN) reported GAAP revenue of $1.02B (+21.5% vs. FY2024 revenue of $837.3M , and +42.8% cumulative change since FY2023) , GAAP net income of -$342.6M, operating cash flow of -$276.4M, and free cash flow of -$276.9M (-18.9% YoY). On the balance sheet, VRDN closed FY2025 with $899.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.02B | -$342.6M | -$276.4M | -$276.9M | $899.4M | — |
| FY2024 (FY) | 2024-12-31 | $837.3M | -$269.9M | -$232.3M | -$232.8M | $742.4M | $20.6M |
| FY2023 (FY) | 2023-12-31 | $712.5M | -$237.7M | -$184.2M | -$184.2M | — | — |
3. VRDN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs VRDN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Viridian Therapeutics Inc. (NASDAQ: VRDN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $25.30 (+2.55% 1D, market cap $2.79B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, VRDN ranks #359 in composite RQD confidence.
How does VRDN compare to VCRE and MBX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VRDN carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VCRE (Vicore Pharma Holding AB) holds a D grade (49/100 RQD, P/E N/A, ROIC —, cap $2.76B) and MBX (MBX Biosciences Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -26.4%, cap $2.69B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).
What are the biggest fundamental strengths and SEC risk factors for VRDN?
Per VRDN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001590750), Viridian Therapeutics Inc. generated $1.02B in revenue (+21.5% YoY), -$342.6M in net income, and -$276.9M in free cash flow against $899.4M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is VRDN trading relative to its 50-day, 200-day, and 52-week technical levels?
VRDN last traded at $25.30 (+2.55% on volume of 3,391,297 shares), positioning the stock +16.70% above its 50-day simple moving average ($21.68) and +16.75% above its 200-day simple moving average ($21.67). Across its 52-week range of $13.18 to $34.29, VRDN sits at the 57.4% percentile with a 14-day RSI of 69.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±9.5% ($22.90 to $27.70).
ROARABLE RATING BRIEF • RQD 45/100 (D)
✓ SEC XBRL & RQD VERIFIED
VRDN — Viridian Therapeutics Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Viridian Therapeutics Inc. (VRDN) earns a live Roarable RQD composite score of 45/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $25.30 (+2.55% 1D, market capitalization $2.79B).
- Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -9.85%.
- Whale 13F & Options Flow (15/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Viridian Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry..8B. Reported revenue is — in each of FY 2023, FY 2024, and FY 2025, so the source does not show a revenue-generating model in the reported periods.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Viridian Therapeutics Inc. (VRDN) reported $1.02B in annual revenue (up from $837.3M in FY2024, +21.5% YoY) and -$342.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($712.5M revenue, -$237.7M net income) through FY2025, VRDN scaled operating cash flow to -$276.4M and free cash flow to -$276.9M, backed by $899.4M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D • RQD 45/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -9.85% and institutional whale pillar of 15/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 15/20, sustained execution supports upside toward the upper end of the $13.18 – $34.29 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), VRDN carries a macro regime beta of 1.00 and gross margin of —.
- Key Question #1: Can VRDN sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $1.02B and free cash flow of -$276.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is VRDN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
VRDN Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Viridian Therapeutics Inc. (VRDN) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Yahoo Finance • 1d ago
Viridian Therapeutics (VRDN) Stock May Look Stretched Against Its Sales Base Yahoo Finance report covering Viridian Therapeutics Inc. (VRDN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Moomoo • 1d ago
RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $38 Moomoo report covering Viridian Therapeutics Inc. (VRDN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Viridian Therapeutics (NasdaqCM:VRDN) Stock Forecast & Analyst Predictions Simply Wall St report covering Viridian Therapeutics Inc. (VRDN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
How FDA Approval Will Impact Viridian Therapeutics Stock Yahoo Finance report covering Viridian Therapeutics Inc. (VRDN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
VRDN Q3'26 Earnings: revenue estimate is 4.72M USD TradingView report covering Viridian Therapeutics Inc. (VRDN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Business Wire • 1d ago
Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026 Business Wire report covering Viridian Therapeutics Inc. (VRDN) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Simply Wall St • 1d ago
Analyst Forecasts Just Became More Bearish On Viridian Therapeutics, Inc. (NASDAQ:VRDN) Simply Wall St report covering Viridian Therapeutics Inc. (VRDN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ad-hoc-news.de • 1d ago
Wells Fargo keeps Buy rating for Viridian Therapeutics stock at USD 31 target ad-hoc-news.de report covering Viridian Therapeutics Inc. (VRDN) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
VRDN Bull vs. Bear Conversation Board — What's Your Call at $25.30?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VRDN 🐻 33% BEARISH CONVICTION
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH
🎯 Target: $30.10 (+22.0%)
📌 Pinned Debate Whale/13F flow scores 14/20, the strongest RQD pillar, reflecting institutional accumulation and options positioning, alongside an RBC
Picked up a starter position in VRDN in my $100K Virtual Cash book at $24.67. Whale/13F flow scores 14/20, the strongest RQD pillar, reflecting institutional accumulation and options positioning, alongside an RBC Capital Buy rating with a $38 target.. Trading inside a $13.18–$34.29 52-week range with -9.85% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.
CapAlloc_Nerd 🐂 BULL
@BreakoutHunter Agree on the RQD 45/100 quality, though with 1.0 beta I'm scaling in with half-size at $24.67 and keeping dry powder in case we test $22.94.
CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH
🎯 Target: $18.50 (-25.0%)
Spot @ $24.67 ROIC of -35%, FCF yield of -9.85%, and operating losses widening to -$363.4M in FY 2025 against $0.0M reported revenue leave the cash e
Careful chasing VRDN at $24.67. ROIC of -35%, FCF yield of -9.85%, and operating losses widening to -$363.4M in FY 2025 against $0.0M reported revenue leave the cash engine at 7/20.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $18.50 on multiple compression.